Second Wave of Biosimilar Cases Sharpens Patent Counsel Focus

Director Timothy “Tim” J. Shea, Jr. was noted in the article “Second Wave of Biosimilar Cases Sharpens Patent Counsel Focus,” published by Managing IP.

“Biosimilar manufacturers have a lot of motivation to resolve these disputes outside of court too.

Tim Shea, director at Sterne Kessler in Washington DC, says these companies have put a lot of resources into developing biosimilars, and having certainty on when they can launch is worth it.”